Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biohaven Ltd. (NYSE: BHVN) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, shelf registration materials and other documents filed with the Securities and Exchange Commission. These filings offer detailed insight into Biohaven’s status as a global clinical-stage biopharmaceutical company focused on immunology, obesity, neuroscience and oncology.
Through its Form 8-K reports, Biohaven discloses material events such as underwritten public offerings of common shares, block share transactions under its at-the-market offering program, and updates on its New Drug Application for VYGLXIA (troriluzole) in spinocerebellar ataxia. Earnings-related 8-Ks furnish press releases summarizing quarterly financial results, R&D spending, and portfolio reprioritization decisions that concentrate resources on late-stage programs like opakalim, BHV-1300, BHV-1400 and taldefgrobep alfa.
Other filings reference the company’s effective Form S-3 shelf registration statement, prospectus supplements for equity offerings, and legal opinions related to share issuances. These documents outline the terms of capital raises used to fund Biohaven’s clinical pipeline, including its Kv7 ion channel modulators, MoDE and TRAP extracellular degraders, myostatin-activin pathway inhibitors, antibody-drug conjugates and TYK2/JAK1 inhibitor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the implications of financing transactions, regulatory updates, and clinical program disclosures without reading every technical detail. For deeper research, investors can review full-text filings to track trends in Biohaven’s operating expenses, trial progress and regulatory strategy over time.
Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of a total of 34,684 common shares on 2026-03-17. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares.
A separate 17,342-share transfer is shown as indirectly held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust is for the benefit of family members other than the reporting person, and Mehta disclaims beneficial ownership of the securities held by the trust.
Biohaven Ltd. is asking shareholders to approve three items at its 2026 annual meeting: elect three directors to serve until 2029, ratify Ernst & Young LLP as auditor for 2026, and approve on an advisory basis executive compensation.
The proxy highlights 2025 R&D progress, including extracellular protein degrader programs in IgA nephropathy and Graves’ disease, an epilepsy candidate opakalim with seizure reduction data, and obesity drug taldefgrobep entering Phase 2. Oncology antibody–drug conjugate programs and several discovery-stage assets are also described.
The board has eight members, six deemed independent, with a combined chair/CEO and a lead independent director. As of March 3, 2026, 150,420,584 common shares were outstanding; two institutional holders each own more than 5%. The company emphasizes financial discipline, equity ownership guidelines, and standard NYSE-aligned governance practices.
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported an award of stock options on a Form 4. He acquired 175,000 stock options as a grant, bringing his directly owned derivative holdings in this award to 175,000 options. The options vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, as long as he continues serving the company on each vesting date. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gentile Kimberly reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. reported that senior vice president of clinical operations Kimberly Gentile received a grant of stock options covering 175,000 shares. The options were awarded on February 27, 2026 and will vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, conditioned on her continuous service with the company.
Biohaven Ltd. reported that its VP and Chief Accounting Officer, Clark George C., received a grant of stock options covering 50,000 shares of the company’s stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
The options vest in four equal installments on February 27 of each year from 2026 through 2029, and each vesting tranche requires Clark George C. to remain continuously employed by Biohaven through the relevant vesting date.
Biohaven Ltd. Chief Scientific Officer Bruce Car received a grant of stock options on February 27, 2026. The award covers 175,000 stock options with an exercise price of $0.00 per share, giving him the right to buy Biohaven shares if he chooses to exercise in the future.
The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each installment requires his continuous service with the company through the relevant vesting date. After this grant, he directly holds 175,000 derivative securities in the form of stock options.
Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. Chief Executive Officer Vlad Coric reported receiving a grant of stock options on February 27, 2026. The award covers 550,000 stock options with a stated price per share of $0.00, increasing his directly held option position to 550,000 derivative securities.
According to the footnote, the options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each vesting is conditioned on his continuous service with Biohaven on the relevant vesting date.
Biohaven Ltd. reported another year of heavy investment in its pipeline, posting a 2025 net loss of $738.8M, or $6.86 per share, compared with a $846.4M loss in 2024. Research and development expenses were $635.1M, down from $795.9M, reflecting prior one-time costs and a shift toward three late-stage programs in immunology, epilepsy and obesity.
Cash, cash equivalents, marketable securities and restricted cash totaled about $322.0M as of December 31, 2025. After year-end, Biohaven raised net proceeds of $178.9M by issuing 17.2 million common shares and had previously completed a roughly $200M 2025 equity offering and an Oberland Capital financing of up to $600M.
The company highlighted strong early clinical signals from its MoDE™ and TRAP™ degrader platform (BHV‑1300 for Graves’ disease and BHV‑1400 for IgA nephropathy), its Kv7 ion channel activator opakalim for focal epilepsy, and myostatin‑activin inhibitor taldefgrobep for obesity, with multiple pivotal and Phase 2/3 readouts expected in the second half of 2026.
Biohaven Ltd. is a biopharmaceutical company focused on immunology, neuroscience, and oncology, highlighting a shift toward three late-stage “key programs.” These include the IgG degrader BHV-1300 for Graves’ disease and other autoimmune conditions, the TRAP degrader BHV-1400 for IgA nephropathy, and the Kv7 activator opakalim for epilepsy.
The report describes strong Phase 1 data for BHV-1300 and BHV-1400 and plans to start pivotal trials for Graves’ disease and IgA nephropathy in 2026. It also outlines the myostatin inhibitor taldefgrobep alfa in obesity and spinal muscular atrophy, and extensive work on the glutamate modulator troriluzole in spinocerebellar ataxia. However, the FDA issued a Complete Response Letter for the SCA New Drug Application, taldefgrobep did not meet the primary endpoint in spinal muscular atrophy, and opakalim failed primary endpoints in major depressive disorder and bipolar disorder, underscoring regulatory and clinical risk.